Under the terms of the agreement, the generic products will be developed and registered by Zydus Pharmaceuticals and manufactured by Zydus Cadila at its USFDA-approved plant in Ahmedabad, Zydus said on Wednesday.
Mallinckrodt will market and sell the products under a joint Mallinckrodt-Zypharma label, it added.
The strategic pact between the two companies is for a period of five years and would be extended further by mutual consent, it said.
Zydus has received approvals to market Atenolol and Clindamycin from the USFDA, it added.
